Novel 1,2,3-triazole derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain.

Novel 1,2,3-triazole derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain.

Journal of medicinal chemistry (2011-07-23)

Nubia Boechat, Vitor F Ferreira, Sabrina B Ferreira, Maria de Lourdes G Ferreira, Fernando de C da Silva, Monica M Bastos, Marilia Dos S Costa, Maria Cristina S Lourenço, Angelo C Pinto, Antoniana U Krettli, Anna Caroline Aguiar, Brunno M Teixeira, Nathalia V da Silva, Priscila R C Martins, Flavio Augusto F M Bezerra, Ane Louise S Camilo, Gerson P da Silva, Carolina C P Costa

PMID21776985

ABSTRACT

The purpose of this study was to prepare various 4-substituted N-phenyl-1,2,3-triazole derivatives using click chemistry. The derivatives were screened in vitro for antimicrobial activity against Mycobacterium tuberculosis strain H37Rv (ATCC 27294) using the Alamar Blue susceptibility test. The activity was expressed as the minimum inhibitory concentration (MIC) in μg/mL (μM). Derivatives of isoniazid (INH), (E)-N'-[(1-aryl)-1H-1,2,3-triazole-4-yl)methylene] isonicotinoyl hydrazides, exhibited significant activity with MIC values ranging from 2.5 to 0.62 μg/mL. In addition, they displayed low cytotoxicity against liver cells (hepatoma HepG2) and kidney cells (BGM), thereby providing a high therapeutic index. The results demonstrated the potential and importance of developing new INH derivatives to treat mycobacterial infections.

MATERIALS

Product Number

Brand

Product Description

R3501

Sigma-Aldrich

Rifampicin, ≥95% (HPLC), powder or crystals

I3377

Supelco

Isoniazid, analytical standard, ≥99% (TLC)